Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.
BPC-157 and TB-500 (Thymosin Beta-4 fragment) are two distinct research peptides frequently studied together in tissue-repair research protocols. BPC-157 is a synthetic fragment derived from a gastric protective protein, studied for its proposed role in angiogenesis and gastrointestinal mucosal repair. TB-500 is a synthetic fragment of Thymosin Beta-4, an actin-regulating peptide studied for its proposed role in cell migration and tissue remodeling. Combined-protocol research explores whether their distinct mechanisms — angiogenic signaling and actin-cytoskeleton regulation — produce complementary effects in soft-tissue research models.
BPC-157 is proposed to act partly through upregulation of VEGF receptor-2 expression and modulation of nitric oxide pathways relevant to tissue vascularization. TB-500 is proposed to act by binding actin monomers, influencing cytoskeletal dynamics involved in cell motility. Research combining the two is designed to probe whether these separate pathways interact additively in models of tendon, ligament, and soft-tissue injury.
Both peptides in this stack are supplied as lyophilized powder requiring reconstitution before laboratory use. Reconstitution and storage should follow each compound’s own specification sheet and the researcher’s institutional protocol. A reconstitution reference tool for converting a target concentration into the correct dilution volume is available to all site visitors.
Providers should request COAs for both individual peptides, not only a combined-product COA, to confirm the blend ratio and each component’s independent quality.
Full pricing and ordering are available exclusively to verified providers.
The BPC-157 and TB-500 stack refers to research involving two distinct peptides studied in tissue-repair and remodeling models. BPC-157 and TB-500 have different proposed mechanisms, making their combined use an area of preclinical research.
BPC-157 is a synthetic peptide fragment studied in preclinical models involving tissue repair, angiogenic signaling, gastrointestinal systems, and vascular-related pathways. Findings from these models should not be interpreted as established clinical effects.
TB-500 is a synthetic fragment associated with Thymosin Beta-4 research. Studies have examined actin-related signaling, cell migration, and tissue-remodeling processes in experimental models.
The research rationale is based on their different proposed mechanisms. BPC-157 research has examined vascular and angiogenic pathways, while TB-500 research focuses in part on actin regulation and cell migration. Combined protocols can therefore be used to investigate potential interactions between these pathways.
BPC-157 has been investigated in relation to pathways involving VEGF receptor-2 and nitric oxide signaling. TB-500, as a Thymosin Beta-4 fragment, is studied in relation to actin dynamics and cellular migration. These mechanisms remain areas of experimental research.
No. Research involving the combination remains primarily preclinical, and evidence from experimental models should not be presented as proof of an established clinical protocol or therapeutic benefit.
These products are intended for laboratory research use only. They are not drugs, foods, cosmetics, or medical treatments and must not be used for any form of human or animal administration. All information provided is for educational and scientific reference only and the products should be handled exclusively by licensed, qualified professionals. Misbranding, misuse, or mislabeling of these products as therapeutic or consumable substances is strictly prohibited by law.
CellGenic ships exclusively to Mexico, Argentina, Colombia, and Perú under local license. Verified-provider-only platform from CellGenic.